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Recently, transradial intervention (TRI) 
has been widely used for percutane-
ous coronary intervention (PCI). Over 
the past decades, TRI has become very 
efficacious even during complex proce-
dures, given the remarkable advances 
in interventional devices. ST elevation 
myocardial infarction (STEMI) is high-
ly thrombotic, associated with a high 
bleeding risk if antiplatelet and anti-
coagulation agents are given; bleeding 
complications compromise clinical 
outcomes. Several studies have demon-
strated the efficacy and safety of TRI 
compared to transfemoral intervention 
(TFI) in STEMI patients [1-4]. These 
studies include the Radial Versus Femo-
ral Access for Coronary Angiography or 
Intervention (RIVAL) study, the ST-Seg-
ment Elevation Myocardial Infarction 
Treated by Radial or Femoral Approach 
in a Multicenter Ran domized Clinical 
(STEMI-RADIAL) trial, and the Radial 
versus Femoral Randomized Investi-
gation in ST-segment Elevation Acute 
Coronary Syndrome (RIFLE-STEACS) 
study. All reported significant reduc-
tions in access site-related complica-
tions, lower mortality, and fewer net 
clinical adverse events (NACE) in acute 
coronary syndrome (ACS) patients in-
cluding STEMI patients, attributable 
principally to significant reductions in 
bleeding and all-cause mortality. The 
Minimizing Adverse Haemorrhagic 
Events by TRansradial Access Site and 
Systemic Implementation of AngioX 
(MATRIX) trial confirmed that TRI 
improved outcomes compared to TFI, 
affording consistent benefits across 
the entire spectrum of ACS patients 
including STEMI patients [4]. A 2018 
meta-analysis of 31 studies reported in 
the Cochrane database [5] found that 
TRI reduced 30-day short-term NACE, 
cardiac death, all-cause mortality, bleed-
ing, and access site complications; but 
insufficient evidence was available in 
terms of long-term clinical outcomes. 
In the current issue, Li et al. [6] de-
scribe the outcomes of TRI, including 
relatively long-term NACE, in STEMI 
patients. TRI for STEMI patients 
undergoing primary PCI featuring 
drug-eluting stents was associated 
with lower incidences of access site 
hematoma, 12-month repeat revascu-
larization, and NACE compared to TFI, 
as has been found in previous studies. 
Interestingly, the repeat revasculariza-
tion rate was significantly lower in the 
TRI group. The authors consider that 
this is explained by the complex le-
sional subset; complex patients might 
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not be adequately handled in statistical terms because 
data were not randomized. Also, image-guided PCI was 
more frequent in the TRI group. This finding should 
be confirmed in a large-scale, long-term, prospective 
randomized study. No significant differences in the 
revascularization rates associated with either approach 
were apparent in previous short-term studies. 
Additionally, upon subgroup analysis of MATRIX 
data, the effects of radial versus femoral access were 
consistent across most subgroups including those de-
fined by age, sex, body mass index, planned or actual 
prescription of prasugrel or ticagrelor versus clopi-
dogrel, diabetes status, renal function, or a history of 
peripheral vascular disease. However, TRI afforded 
significantly better outcomes in high-volume centers 
(where over 80% of patients underwent TRI) [4], but 
TRI was associated with more operator and patient ra-
diation exposure [7]. 
Conclusively, the evidence (including the findings 
of this study) suggests that TRI should be the first-line 
approach for patients, including STEMI patients who 
are hemodynamically stable, especially in high-volume 
TRI centers, with care taken to provide appropriate ra-
diation shielding.
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